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RESEARCH ARTICLE
Fine-tuning the onset of myogenesis by homeobox proteins that
interact with the Myf5 limb enhancer
Philippe Daubas1,*, Nathalie Duval1,‡, Lola Bajard1, Francina Langa Vives2, Benoît Robert1,
Baljinder S. Mankoo3,§ and Margaret Buckingham1,§
ABSTRACT
Skeletal myogenesis in vertebrates is initiated at different sites of
skeletal muscle formation during development, by activation of
specific control elements of the myogenic regulatory genes. In the
mouse embryo, Myf5 is the first myogenic determination gene to be
expressed and its spatiotemporal regulation requires multiple
enhancer sequences, extending over 120 kb upstream of the Mrf4-
Myf5 locus. An enhancer, located at −57/−58 kb from Myf5, is
responsible for its activation in myogenic cells derived from the
hypaxial domain of the somite, that will form limb muscles. Pax3 and
Six1/4 transcription factors are essential activators of this enhancer,
acting on a 145-bp core element. Myogenic progenitor cells that will
form the future muscle masses of the limbs express the factors
necessary forMyf5 activation when they delaminate from the hypaxial
dermomyotome and migrate into the forelimb bud, however they do
not activate Myf5 and the myogenic programme until they have
populated the prospective muscle masses. We show that Msx1 and
Meox2 homeodomain-containing transcription factors bind in vitro
and in vivo to specific sites in the 145-bp element, and are implicated
in fine-tuning activation of Myf5 in the forelimb. Msx1, when bound
between Pax and Six sites, prevents the binding of these key
activators, thus inhibiting transcription of Myf5 and consequent
premature myogenic differentiation. Meox2 is required for Myf5
activation at the onset of myogenesis via direct binding to other
homeodomain sites in this sequence. Thus, these homeodomain
factors, acting in addition to Pax3 and Six1/4, fine-tune the entry of
progenitor cells into myogenesis at early stages of forelimb
development.
KEY WORDS: Myf5 transcription, Msx1, Meox2, Mouse embryo,
Limb myogenesis
INTRODUCTION
Skeletal muscles in the trunk and limbs derive from myogenic
progenitor cells present in the somites of the vertebrate embryo and
their formation depends on myogenic regulatory factors controlling
muscle cell determination and differentiation (see Tajbakhsh and
Buckingham, 2000). Myf5 is expressed at the onset of myogenesis
in the mouse embryo (Ott et al., 1991) when, together with Mrf4, it
determines myogenic cell fate (Braun et al., 1992; Kassar-
Duchossoy et al., 2004). Thereafter, MyoD is expressed and can
direct cells into the myogenic programme when Myf5 and Mrf4 are
absent (Braun et al., 1992). The absence of these three myogenic
determination factors leads to the absence of skeletal muscles
(Kassar-Duchossoy et al., 2004; Rudnicki et al., 1993). Skeletal
muscle in the limbs is formed by muscle progenitor cells that
delaminate from the hypaxial dermomyotome of the somites and
migrate into the limb field. These cells express the paired/
homeodomain transcription factor Pax3 and in its absence they
fail to migrate and subsequently undergo apoptosis (see
Buckingham and Relaix, 2007). Migration in response to the
ligand HGF depends on the c-met receptor (Bladt et al., 1995), and
on CXCR4, the receptor for the ligand SDF, which like HGF, is
expressed by mesenchymal cells in the limb bud (Vasyutina et al.,
2005). The c-met gene is a target for Pax3 (Epstein et al., 1996) and
CXCR4 is genetically downstream of Lbx1 which is also expressed
in Pax3-positive migratory cells. In the absence of Lbx1, the ventral
muscle mass fails to form and these myogenic progenitors remain in
the vicinity of the somite where they can adopt other cell fates (see
Buckingham, 2001; Schäfer and Braun, 1999). Six homeodomain
factors, like Pax3, are important upstream regulators of myogenesis
(see Buckingham and Relaix, 2007) and Six1/4 are also expressed in
myogenic progenitors that migrate to the limbs. In the absence of
Six1/4, limb muscles do not form correctly and Pax3 expression in
the hypaxial somite is compromised (Grifone et al., 2005).
Transcriptional regulation of the myogenic determination genes
has been extensively studied. Myf5 and Mrf4 are closely linked on
mouse chromosome 10 and their transcriptional regulatory elements
extend over a region of at least 120 kb, 5′ to and within the Mrf4-
Myf5 locus. A number of enhancers have been characterised which
direct different aspects of the complex spatiotemporal regulation of
Myf5 in the embryo (see Buckingham and Vincent, 2009; Carvajal
and Rigby, 2010; Daubas and Buckingham, 2013; Moncaut et al.,
2012; Ribas et al., 2011).
A regulatory region required for Myf5 transcription in the limb
and in the more mature hypaxial somite is located at −48/−58 kb 5′
of Myf5 (Hadchouel et al., 2000). Within this region, complete
expression in the developing limbs requires the concerted activity of
at least three sub-regions, with the main limb enhancer located at
−57/−58 kb (Hadchouel et al., 2000, 2003). Within this enhancer a
145-bp core sequence contains an essential Pax3 paired domain
binding site (Bajard et al., 2006) and an adjacent Six1/4 binding site,
required for complete activity (Giordani et al., 2007). Mutation in a
homeodomain X-vent-type site, between the Pax and Six sites,
negatively affects enhancer activity (Buchberger et al., 2007). Pax3
and Six1/4 are expressed in myogenic progenitor cells that migrateReceived 13 August 2015; Accepted 2 September 2015
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into the limb buds prior to Myf5 activation. Within the developing
limb, a proportion of these cells will proliferate, with subsequent
expression of Pax7, and do not immediately enter the myogenic
programme (see Buckingham and Relaix, 2007). Once myogenic
progenitor cells have populated the prospective limbmuscle masses,
Sonic Hedgehog (Shh) drives myogenesis specifically within the
ventral muscle mass, to enhance Myf5 transcription through
essential Gli-binding sites located immediately 3′ of the core 145-
bp element in the −57/−58 kb enhancer (Anderson et al., 2012).
However during the delamination/migration of the myogenic
progenitor cells, it is not clear what other regulatory factors
interact with the 145-bp sequence to prevent premature activation of
Myf5. When this sequence is present in multiple copies in a reporter
transgene, premature activation is observed, suggesting saturation of
potential repressor mechanisms (Bajard et al., 2006). Two other
homeodomain factors, Meox2 and Msx1, are also expressed in
migratory limb myogenic progenitor cells. InMeox2 mutants,Myf5
activation in the limb buds is delayed and there are later muscle
defects, attributed to secondary effects of Meox2 in connective
tissue (Mankoo et al., 1999). Meox2 binds in vitro to the Xvent2
sequence, but when a BAC transgene encompassing the entireMrf4/
Myf5 locus and regulatory regions was placed in a Meox2 mutant
background no effects on Myf5-nLacZ expression were detected
(Buchberger et al., 2007). Msx1 is expressed in mesenchymal cells
throughout the early forelimb bud, and also in the myogenic
progenitor cells that migrate from the mouse somite to the forelimbs
(Houzelstein et al., 1999). In contrast,Msx2 has a distinct expression
pattern but its expression in myogenic cells has not been reported.
Msx1 is known to inhibit myogenic differentiation (Song et al.,
1992) and MyoD activation (Woloshin et al., 1995) when over-
expressed in cultured muscle cells and has been shown to recruit the
repressive polycomb complex (Wang et al., 2011). ChIP Seq
experiments in an ex vivo over-expression context, show Msx1
binding to the MyoD core enhancer and to the −57/−58 kb Myf5
regulatory region. Over-expression of Msx1 in the chick limb bud
prevented MyoD activation and resulted in reduced skeletal muscle
formation, with a proposed mechanism through direct repression by
Msx1 binding to the MyoD core enhancer and also by Msx1/Pax3
complex formation that inhibits Pax3 binding to its targets (Bendall
et al., 1999). We therefore decided to investigate more closely the
potential role of Msx1 and Meox2 homeodomain factors in
modulating the activity of the 145-bp core element of the Myf5
limb enhancer in myogenic progenitor cells that migrate to the
forelimb, at the onset of myogenesis in the mouse embryo.
RESULTS
Meox2 and Msx homeoproteins bind in vitro to the 145-bp
Myf5 enhancer
We first examined the 145-bp Myf5 regulatory element for
homeodomain consensus binding (HBox) sequences (Noyes
et al., 2008), in addition to the binding sites for Pax3 (Bajard
et al., 2006) and Six1/4 (Giordani et al., 2007) which are known to
be functionally important. Three binding sites, HBox1, 2 and 3 were
identified (Fig. 1A), where HBox2 is part of the previously
described Xvent2 site (Buchberger et al., 2007) and HBox1 and 3
are located 5′ and 3′ respectively of the central Pax3-HBox2-Six1/4
domain. Electrophoretic mobility shift assays (EMSA) show that
Meox2 protein interacts with all three HBox sequences (Fig. 1B).
Specificity of interaction is shown by the presence of supershifted
bands with anti-Meox2 antibodies (Fig. 1B, lanes 2) and by
competition with an excess of unlabelled probe, but not with a probe
in which the HBox sequence is mutated (see Fig. 1B, lanes 3, 4 for
HBox2 example). Meox2 binding is abolished when the HBox sites
are mutated (results not shown). Similar experiments withMsx1 and
Msx2 proteins show that they bind HBox2 (Fig. 1C, lanes 2 and 4),
but not HBox1 and 3 (results not shown). In the absence of reliable
Msx antibodies, recombinant proteins with haemaglutinin
(C-terminal-HA) or Flag (C-terminal-Flag) tags for Msx1 or
Msx2 respectively were used. Antibodies against HA or Flag
substantially reduced binding (Fig. 1C, lanes 3 and 5). In this case a
supershift is not seen, presumably because the protein/DNA
complex is disrupted. In conclusion, Meox2 protein can bind in
vitro to HBox1, 2 and 3, whereas Msx1/2 binds only to HBox2 of
the 145-bp Myf5 regulatory sequence.
Meox2 or Msx1 do not bind in vitro simultaneously with Pax3
or Six proteins to the HBox2 region
The close proximity of Pax3 and Six1/4 binding sites to the HBox2
site, which binds Meox2 and Msx proteins, raises the question of
whether these proteins can bind simultaneously. We used limiting
molar amounts of labelled DNA probe to test this in gel shift assays.
Binding of Pax3 and Six4 together is demonstrated by the
appearance of a supplementary slower migrating band (Fig. 2A,
lane 5) which is disrupted when either anti-Pax3 or anti-Six4
Fig. 1. EMSA experiments showing that the 145-bpMyf5 element contains
HBox sites towhichMeox2 andMsx1/2 proteins bind in vitro. (A) The DNA
sequence of the 145-bpMyf5 enhancer. HBox1-3 binding sites are in red. Blue
letters above the sequence show nucleotide changes inmutated oligos used in
EMSA. HBox1-3 DNA probes used in gel shifts are indicated by solid lines
under the sequence. Pax3 (black) and Six1/4 (green) binding sites (Bajard
et al., 2006; Giordani et al., 2007) are indicated in bold. (B) EMSA experiments
were performed using 3 different DNA probes containing putativeHBox1, 2 or 3
binding sites. In vitro synthesized Meox2 protein was added to the probes
(lanes 1-2) and polyclonal anti-Meox2 antibodies were subsequently added
(lanes 2). Each probe binds Meox2 protein and the complex is supershifted
when antibodies are added (asterisks). Competition with unlabelled probe is
shown for HBox2 (lanes 3, 4). A 200 molar excess of unlabelled probe
competes the binding (lane 3), whereas unlabelled probe with a mutated
binding site does not compete (lane 4). A control with crude reticulocyte lysate
is shown in lane C. (C) Example of an EMSA experiment showing that Msx1
and 2 proteins can bind to the HBox2 probe. Binding occurs when Msx1-
Cterm-HA (Msx1-HA) or Msx2-Cterm-Flag (Msx2-F) proteins are present
(lanes 2 and 4) and specificity is demonstrated by the reduction of the shifted
bands when antibodies, anti-HA (lane 3) or anti-Flag (lane 5), are added.
Controls are shown with crude reticulocyte lysate (lane C) or with Pax3 protein
as a positive control (lane 1).
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Fig. 2. EMSA experimentswith combinations of proteins to test co-binding or competition on theHBox2 probe.The labelled HBox2 probe, which contains
Pax3 and Six binding sites was used in limiting molar amounts, compared to the proteins added. (A) Pax3 and Six4 proteins can bind together to the same DNA
sequence. Pax3 binding (lane 1) is supershifted with anti-Pax3 antibodies (lane 2, asterisk). Six4 binding (lane 3) is supershifted when anti-Six4 antibodies are
present (lane 4, asterisk). When both proteins are present, an additional slower migrating band is detected (lane 5, arrow) and the intensity of the band
corresponding to Six4 binding alone is reduced, compared to lane 3. When anti-Pax3 (lane 6) or anti-Six4 (lane7) antibodies are added, this band, which is
therefore due to co-binding of Pax3 andSix4 on the same oligo, is disrupted and the bands due to Pax3 or Six4 binding alone are supershifted. Similar results were
obtained with Pax3 and Six1, with disruption of the Pax3/Six1 complex with anti-Pax3 antibodies (results not shown). Lane C is the control with crude lysate.
(B) Meox2 and Six1/4 co-binding is not detectable. EMSA was performed with constant amounts of Meox2 and increasing amounts of either Six1 (left side of
panel) or Six4 (right side of panel). Presence of anti-Meox2 (lanes 5) or anti-Six1 (left, lanes 6,8) or Six4 (right, lanes 6,8) antibodies are indicated above the panel.
No additional slower migrating band, suggesting co-binding of Meox2 and Six proteins, is detected. A weak band (indicated by an arrow) was detected in most
samples, including the control with crude lysate (laneC). Asterisks indicate the position of bands supershifted byantibodies. (C) Meox2 andPax3 co-binding is not
detectable. In the presence of constant amounts of Meox2 (left side of panel), no Pax3 (lane 1) or increasing amounts of Pax3 were added (lanes 2-4). No
supplementary band is detected when both proteins are present. Controls are shown with Pax3 alone (lane 7) or with Pax3 and anti-Pax3 antibody (lane 8) or
lysate alone (C). In the presence of constant amounts of Pax3 (right side of panel), noMeox2 (lane 1) or increasing amounts of Meox2 were added (lanes 2-4). No
additional slower migrating band is detected when both proteins are present in the binding reaction. Aweak band (arrow) was detected in most samples, including
those without Meox2 and appears to represent a Pax3 complex with this lysate. Addition of anti-Meox2 (lanes 5, 8) or anti-Pax3 (lane 6) antibodies disrupt the
bandshifts and, in the case of Pax3, generate a supershift (asterisk). Controls are shown with Meox2 alone (lane 7) or with Meox2 and anti-Meox2 antibody
(lane 8). (D) Msx1 and Six4 co-binding is not detectable. Increasing amounts of Msx1 alone (lanes 1-3) or with constant amounts of Six4 added at the same time
(lanes 4-6) do not produce an additional slower migrating band when both proteins are present. Six4 binding is reduced when higher amounts of Msx1 are added
(lanes 4-6). This displacement occurs even if Six4 protein is added before Msx1 (lanes 7-9). (E) Msx1 binding is displaced by increasing amounts of Pax3. When
constant amounts of Msx1 without (lane 1) or with 2.5, 5, or 10 fold amounts of Pax3 (lanes 1-4) are added, reduction of Msx1 binding is seen as Pax3 levels
increase, under gel conditions which facilitate distinction of Pax3 andMsx1 binding with lower levels of Pax3. This is confirmed by the histogram showing a scan of
this autoradiograph with ImageJ 1.47v. (F) Msx1 and Pax3 can bind together when the spacing between the sites is increased. One copy of a mutated HBox2*
site, which does not bindMsx1 (see Fig. 4), was intercalated on either side of the bona fide HBox2 site, thus increasing the distance between Pax3 and Six binding
sites. In the presence of constant amounts of Msx1 (lanes 2-6) and increasing amounts of Pax3 (lanes 3-5), a supplementary slower migrating complex appears
(arrow). When anti-Pax3 antibody is added, this band disappears and Pax3 complexes are supershifted (asterisk, lane 6). This band does not appear if Pax3 is
added alone (lane 7) but is detected when Pax3 andMsx1-HA proteins are added together or sequentially (lane 8) and disappears if anti-HA antibodies are added
(lane 9). Note that bands corresponding to Pax3 or Msx1-HA complexes alone migrate at almost the same positions as shown in Fig. 1 (G) The drawing resumes
the competition between homeoproteins such asMsx1 andMeox2 andPax3/Six proteins for in vitro binding to the oligonucleotide probe in the EMSA experiments
presented. The binding of a homeoprotein at the HBox2 site (red) prevents the binding of Pax3 or Six1/4.
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antibodies are added (Fig. 2A, lanes 6, 7). A similar result was
obtained with Pax3 and Six1 proteins (not shown). This indicates
that Pax3 and Six proteins can bind together on the same Pax3/
HBox2/Six DNA sequence. In contrast, when constant amounts of
Meox2 are added,with increasing amounts of either Six1 or Six4, we
found no evidence for co-binding on HBox2 and Six binding sites
since no supplementary slower migrating band was detected
(Fig. 2B). When constant amounts of Meox2 are added with
increasing amounts of Pax3, or constant amounts of Pax3 with
increasing amounts of Meox2, no supplementary band was
detectable and we conclude that Pax3 and Meox2 cannot bind
simultaneously on the same DNA sequence (Fig. 2C). Similar
experiments with Msx1 and Six4 proteins (Fig. 2D) also indicated
that Msx1 cannot bind together with Six4. In these experiments,
competition for DNA binding was observed. When increasing
amounts of Msx1 are added, Six4 binding is disrupted (Fig. 2D,
lanes 4-6). This also occurs ifMsx1 is added subsequently, after Six4
binding to the oligo (lanes 7-9). Competition is also observed
between Pax3 and Msx1 and is illustrated in Fig. 2E, where
increasing amounts of Pax3, relative to a constant amount of Msx1,
led to a diminution of Msx1 binding. Again no additional slower
migrating band was observed, even on long exposures of the
autoradiogram (result not shown). In order to test whether steric
hindrance is the cause of this competition, we engineered an
elongated version of the probe where a mutated HBox2* sequence,
which does not bind Msx but does not interfere with Pax3 binding
(see Fig. 4), is introduced on both sides of the bona fide HBox2 site,
increasing the distance between the Pax3 and Six1/4 sites. In this
case, we can detect an additional slower migrating band, indicating
that Pax3 andMsx1 are bound to the same elongated DNA sequence
(Fig. 2F). We therefore propose that homeodomain protein binding
to the HBox2 site interferes with binding of Pax3, which is essential
for the function of the 145-bp Myf5 regulatory sequence (Bajard
et al., 2006). Interference with Six binding will also have a negative
impact on the activity of the limb enhancer (Giordani et al., 2007).
Thismay be important in preventing premature activity of the 145-bp
sequence in migrating myogenic progenitors which contain Pax3
and Six factors, but in which Myf5 is not yet transcribed (Fig. 2G).
Meox2 and Msx1 bind the 145-bp Myf5 sequence in vivo
We next investigatedMsx1 andMeox2 binding in vivo to the 145-bp
Myf5 regulatory sequence by chromatin immunoprecipitation
(ChIP) experiments, using sonicated chromatin prepared from the
thoracic region of the trunk including the forelimbs of embryonic
day (E)10-E10.5 mouse embryos. An anti-Meox2 antibody was
used on wild-type embryos, and anti-HA antibodies were used to
immunoprecipitate HA-tagged Msx1 protein prepared from
Msx1Tag/Tag embryos. The Tag does not interfere with Msx1
function (Duval et al., 2014). ChIP results are presented as a ratio of
binding to the 145-bp element at−57.5 kb compared to that obtained
with two negative control regions at −275.5 kb and −55.2 kb
upstream of the Myf5 locus, previously used as control for ChIP
(Bajard et al., 2006; Giordani et al., 2007). Msx1 binding is not
observed with chromatin from interlimb regions excluding limb
buds, of E10.5 embryos (Fig. 3). These experiments therefore show
in vivo binding of Msx1 and Meox2 to the 145-bp sequence at
forelimb level.
Functional importance of the HBox2 site for the correct
timing of Myf5 activation in forelimb buds
Pax3, Six1/4, Meox2 and Msx1 are all expressed in myogenic
progenitor cells of the forelimb (Houzelstein et al., 1999; Mankoo
et al., 1999; Relaix and Buckingham, 1999) butMyf5 is not activated
until these cells have migrated from the hypaxial somite into the
forelimb bud, at the 35 somite stage (E10.5) (Tajbakhsh and
Buckingham, 1994). Since both Meox2 and Msx1 proteins bind to
HBox2, we investigated the importance of this binding site in
regulating the activation ofMyf5. We screened to find a mutation in
or close to HBox2 that prevents Msx1 and Meox2 binding without
disrupting the essential binding of Pax3 and Six1/4. Single
nucleotide mutations were introduced (Fig. 4A) and the resulting
DNA sequences tested for Pax3, Six1/4, Msx1 and Meox2 binding
by EMSA. Mutations 2 and 3 abolished both Pax3 and Msx1
binding. Mutation 1 perturbed Msx1 binding and gave additional
bands with the reticulocyte lysate. Mutations 4 and 5 both abolished
Msx1 binding. In these mutations, Pax3 and/or Six1 binding was
also affected (results not shown). This effect on Pax3 and Six1/4
binding probably explains the loss ofMyf5 expression after mutating
the Xvent2 site, reported by Buchberger et al. (2007). However we
found that mutation 6 (namedMut6-HBox2*) does not perturb Pax3
or Six binding whereas the interaction with both Msx1 (lane 5) and
Meox2 (lane 6) was severely compromised (Fig. 4B). The effect of
this HBox2* mutation was then tested in vivo by transient
transgenesis. For these experiments the −58/−57 kb region
containing the 145-bp sequence, which gives robust expression,
was placed in front of the Myf5 proximal promoter region and the
nLacZ reporter. Embryos were collected at E10.5. The HBox2*
mutation resulted in premature activation of the transgene, with
excessive β-galactosidase labelling in the forelimb bud (Fig. 4C,D)
compared to that obtained with the transgene containing a wild-type
Hbox2 sequence (Fig. 4H,I). Labelling in the branchial arches and
variable labelling in the neural tube is due to sequences present in the
proximal promoter region (Carvajal et al., 2001) and was observed
with both constructs (Table S2). On serial sections, X-gal staining
shows labelled cells within and adjacent to the hypaxial
dermomyotome (Fig. 4E,F), whereas such cells are very rare in
Fig. 3. Msx1 and Meox2 proteins interact in vivo with the 145-bp Myf5
regulatory sequence. ChIP experiments were carried out with two different
anti-HA antibodies (aHA1-2), to immunoprecipitate chromatin prepared from
the thoracic region of the trunk including forelimb buds (forelimb region), of
E10-E10.5 Msx1Tag/Tag embryos, or with anti-Meox2 antibodies to
immunoprecipitate chromatin prepared from the equivalent region of wild-type
embryos at E10.5. Histograms represent the fold change in occupancy of the
145-bp Myf5 element, versus two different negative control regions located
respectively at −257.5 kb (black) and −55.2 kb (grey) upstream of the Myf5
gene transcription start site (Bajard et al., 2006; Giordani et al., 2007). A control
using IgGs from non-immune serum is shown for experiments with wild-type
chromatin. Results on the right part of the figure were obtained with ChIP on
extracts from interlimb regions, excluding limb buds, ofMsx1Tag/Tag embryos at
E10.5, using anti-HA antibodies or control non immune IgGs. Biological
replicates of these ChIP experiments were carried out with three different
preparations of chromatin. Error bars indicate s.e.m.
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controls (Fig. 4J,K). A magnified view of a section shows an
accumulation of β-galactosidase positive cells adjacent to the somite
in the proximal forelimb bud (Fig. 4G), whereas normally only a few
dispersed β-galactosidase positive cells are present within the limb
(Fig. 4L). Furthermore, with the HBox2* mutated transgene, many
more β-galactosidase-positive cells are present within the limb. This
indicates that premature activation of the transgene also extends to
progenitors within the forelimb, where only a proportion of Pax3-
positive myogenic progenitors normally activate Myf5 and enter
myogenesis, while the rest provides a reserve cell population for
future muscle growth (Buckingham and Relaix, 2007). We therefore
conclude that the HBox2*mutation, which compromises homeobox
protein binding, leads to precocious and ectopic activation of the
Myf5 enhancer in myogenic progenitors of the forelimb bud in vivo.
Role of Msx proteins in the early repression of Myf5 in the
hypaxial somite and forelimb bud
To test the potential role of theMsx1 protein in the delay ofMyf5 gene
activation in myogenic progenitor cells, we examined embryos in
which Msx conditional alleles had been inactivated specifically in
myogenic progenitor cells by the use of a Pax3Cre allele, at E9.75 (28-
30 somites) when they have just begun to delaminate from the
hypaxial dermomyotome and enter the forelimb bud. This is the time
window when Msx1 is maximally expressed in the hypaxial
dermomyotome at forelimb level (Houzelstein et al., 1999). The
efficiency of Cre recombinase to recombine Msx1 floxed alleles in
Pax3 expressing cells was assessed byMsx1 in situ hybridization on
cryosections of Pax3Cre/+Msx1fl/+ and Pax3Cre/+Msx1fl/fl embryos at
E10.5. The control in situ signal was too faint in the hypaxial somite,
but it was clear thatMsx1 transcripts were absent in Pax3Cre/+Msx1fl/fl
embryos, in Pax3 expressing cells of the dorsal neural tube, a region
where Msx1 is also expressed (Liem et al., 1995), whereas Msx1
transcripts are present in the non-myogenic distal mesenchyme of
the forelimb (Fig. S1). In control embryos at this stage (Fig. 5A, left
panel) only rare Myf5-positive (+) cells could be detected in the
hypaxial dermomyotome and in adjacent delaminating cells. In
contrast, in embryos where both Msx1 alleles have been
recombined, Myf5 expression was observed within the Pax3-
expressing population of cells in the hypaxial dermomyotome and in
adjacent delaminating cells (Fig. 5A, middle panel). Pax3
Fig. 4. Mutation of HBox2, without affecting Pax3 and Six1/4 binding, results in premature activation of the −58/−57 kbMyf5 limb enhancer. (A). Single
mutation scanning in the HBox2 binding site (red) region by successive replacements of nucleotides by a cytosine (C) (Mut1 to 6). Pax3 and Six1/4 binding
sites are shown as shadowed boxes. (B) EMSA experiments were performed with the wild-type (WT) sequence or the mutated probe corresponding to Mut6 in
order to test the binding of Pax3, Six1/4, Msx1 and Meox2 in vitro synthesized proteins. Compared with the wild-type sequence (WT), mutation 6 (Mut6-HBox2*)
does not affect the binding of Pax3 (lanes 2), Six 1 (lanes 3) and Six4 (lanes 4), but compromises the binding of Msx1 (lanes 5) and Meox2 (lanes 6) (arrows).
Controls with crude lysate are shown in lanes 1. (C-L) Examples of X-gal stained transient transgenic embryos at E10.5 (35/36 somites), obtained with a
−58/−57baMyf5nLacZ transgene in which the 145-bp sequence within the −58/−57 region contains a mutated HBox2* sequence (C-G) or a wild-type HBox2
(H-L). Whole mount X-Gal stained embryos are shown in C and H, with close-ups of the forelimb region in D and I, where the arrow points to X-gal staining. FL,
forelimb bud, asterisk shows branchial arch expression – this and variable neural tube expression are due to sequences in the Myf5 proximal promoter
region used (baMyf5). (E-G,J-L) Serial cryostat sections at the forelimb level where the plane of section is shown by a line in C for E,F, and in H for J,K. Sections
including the hypaxial somite and proximal forelimb are shown in G and L. These X-Gal stained sections (Myf5-β-Gal) were treated with anti-Pax3 antibodies,
revealed by horse radish peroxidase (PAX3-HRP) to label Pax3-positive myogenic progenitors (HDM, hypaxial dermomyotome).
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expressing cells in the hypaxial region were counted as well as those
co-expressing Myf5. 23.2% of Pax3+ cells are also Myf5+ when
Msx1 alleles are inactivated, compared to 4.5% in control embryos.
Inactivation of both Msx1 and Msx2 alleles gave a similar
percentage of Myf5+ cells/Pax3+ cells (20.6%) (Fig. 5A, right
panel; Fig. 5B). We also examined sections at forelimb bud level at
E10.25 (34-36 somites). Pax3+ cells co-expressing Myf5 are clearly
detected in the dorsal-most part of the forelimb bud, and counting of
these cells showed a similar tendency between control versus Msx1
mutant embryos (9.5% of Myf5+ cells/Pax3+ cells, vs 11.8% -
results not shown). At later stages, differences in the forelimbs
between mutant and wild type were less evident, as shown byMyf5
in situ hybridisation for dorsal muscle masses at E11.5 (Fig. 5C). By
this stage, as previously shown by Houzelstein et al. (1999),
domains of Myf5 expression in the forelimb are adjacent to those
where Msx1-nLacZ is expressed, Myf5 being expressed in future
ventral and dorsal muscle masses and Msx1 in the distal
mesenchyme. We conclude that lack of the Msx1 protein in vivo
leads to premature onset of Myf5 expression in early Pax3-positive
myogenic progenitors as they delaminate from the hypaxial
dermomyotome, but does not affect Myf5 transcription in those
cells that continue to migrate into the developing forelimb bud and
does not affect later myogenesis.
Meox2 is necessary for the early activation of the 145-bp
Myf5 regulatory element
Since the Meox2 protein can bind in vitro to the three HBox sites of
the 145-bp sequence and because Meox2 is also present in limb
myogenic progenitors in vivo, we examined the regulation of early
Myf5 expression by this factor. We crossed Myf5nLacZ/+ mice
(Tajbakhsh et al., 1996) with the Meox2+/− mouse line (Mankoo
et al., 1999) and examined expression between E10.5 and E12.5,
when one or two alleles ofMeox2 are inactivated. There was a clear
delay in nLacZ expression in forelimb buds of the Meox2
homozygous mutant versus heterozygous embryos at 36-39
somite stages (Fig. 6A-C compared with D-F). Our observations
correlate with the decrease in Myf5 transcripts reported at E10.5 in
forelimb buds of Meox2−/− mutant embryos (Mankoo et al., 1999).
We then crossed a transgenic 145-baMyf5nLacZ mouse line, with
theMeox2+/− line and observed the same delay in nLacZ expression
in forelimbs of Meox2−/− mutants at E10.5 (Fig. 6G-L), indicating
that the onset of Myf5 expression in the forelimbs depends on
activation of the 145-bpMyf5 sequence by Meox2 in Pax3-positive
myogenic progenitor cells, which are also clearly present in the
mutant (Fig. S2). This delay does not persist at later stages of
development, when 145-baMyf5-nLacZ expression in forelimb
buds is observed inMeox2−/− embryos at E12.5 (Fig. S3), consistent
with previous observations (Buchberger et al., 2007). At E12.5,
expression of the 145-baMyf5nLacZ transgene in the hindlimb was
delayed in the mutant (Fig. S3). This demonstrates that the
mechanism of Myf5 activation by Meox2 is common to fore- and
hindlimbs. In order to determine whether this is a direct effect, we
examined transgene function when HBox1, 2 and 3, that bind
Meox2, are mutated, using the HBox2* mutation which does not
disrupt the binding of Pax3 and Six1/4. These mutations in the
145-bp sequence were tested in the context of the −58/−57 kbMyf5
Fig. 5. Msx1 Cre-mediated inactivation in Pax3-positive cells leads to premature expression of Myf5 in the hypaxial somite. (A) Immunochemistry on
transverse cryosections at forelimb level of Pax3Cre/+;Msx1fl/+;Msx2fl/+(control, left), Pax3Cre/+;Msx1fl/fl;Msx2fl/+ (M1, middle) and Pax3Cre/+;Msx1fl/fl;Msx2fl/fl
(M1M2, right) embryos at E9.75 (28-30 somites), showingmerged images after immunostaining with anti-Pax3 (green) and anti-Myf5 antibodies (red). Contrary to
control embryos, double positive Myf5+/Pax3+ cells are found in the region of the hypaxial dermomyotome (HDM), indicated by white arrows in the higher
magnification shown for the M1M2 embryo. White lines in merged images represent the upper limit (corresponding to the ventral part of the neighbouring neural
tube) below which Myf5+ cells in the Pax3+ population were counted. The contour of the embryos is marked by a white line. FL, forelimb; DM, dermomyotome;
M, myotome. (B) Histogram representing the percentage of Myf5+ cells among the Pax3+ cells counted in cryosections equivalent to those shown in (A),
with 870-960 Pax3+ cells counted from three embryos for each genotype. Error bars indicate s.e.m. 0.01<*P<0.05; 0.001<**P<0.01; versus control.
(C) Comparison of wild-typeMsx1+/+ andMsx1nLacZ/nLacZ (Msx1−/−) mutant embryos hybridized with an anti-senseMyf5 riboprobe. Whole mount lateral enlarged
views at the forelimb level of embryos at E11.5 are shown.
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enhancer. Compared with the non-mutated -58/-57baMyf5nLacZ
transgene (Fig. 6M), the nLacZ reporter was not expressed in
forelimb buds at E10.5 when all 3 HBox sites were mutated
(Fig. 6N,O). These results demonstrate the role of Meox2 in the
direct activation ofMyf5 through the 145-bp sequence in limb buds
at the onset of myogenesis.
DISCUSSION
The Myf5 myogenic determination gene is not activated in limb
muscle progenitor cells when they delaminate from the somite and
migrate to the limb bud, despite expression of Pax3 and Six1/4
which can activate theMyf5 limb regulatory element. In this context,
we show that direct binding ofMsx1 andMeox2 controls the precise
onset ofMyf5 activation in the forelimb bud in vivo.Msx1 prevents
precocious activation by competing Pax3 and Six1/4 binding while
Meox2 is required to initiate expression once cells have reached the
forelimb buds.
We have characterised three homeodomain-binding sites present
in this 145-bp sequence, located within an enhancer at −58/−57 kb
from theMyf5 gene. We show that all three HBox sites bind Meox2
in vitro and that Meox2 is bound to the 145-bp sequence in vivo in
preparations from the trunk region, including forelimbs, of E10.5
embryos. At this stage, mutation of all three HBox sites results in a
loss of activity of the limb enhancer in −57/−58baMyf5nLacZ
transgenic embryos. Pax3 and Meox2 proteins are co-expressed in
cells that leave the hypaxial dermomyotome and migrate into the
limb (Mankoo et al., 1999). These authors also reported delayed
activation of Myf5 transcription in the early forelimb bud in the
absence of Meox2. We now confirm this with the β-galactosidase
reporter from a Myf5nLacZ allele and conclude from our transgenic
experiments that the HBox sequences in the 145-bp element are
implicated in this delay in –57/–58baMyf5nLacZ transgenic
embryos. This delay is not due to interference with essential Pax3
or Six1/4 binding to adjacent sites, since the HBox2* mutation used
permits Pax3 and Six1/4 binding in vitro and this mutation alone
results in premature activation of the transgene. Pax3 and Meox2
proteins have been shown to interact in vitro with each other
(Stamataki et al., 2001), however in EMSA experiments we saw no
Fig. 6. Meox2 inactivation induces a delay inMyf5 expression in
forelimbbuds,whichoperatesviaHBoxsequences in the145-bp
Myf5 element. (A-F) Lateral views showing X-Gal staining at 36
(A,D), 37 (B,E) and 39 (C,F) somite stages of Meox2+/−Myf5+/nLacZ
(Myf5+/−A-C) or Meox2−/−Myf5+/nLacZ (Myf5+/− D-F) embryos.
Activation of theMyf5nLacZ allele in myogenic progenitor cells in the
forelimb bud is delayed in the absence of Meox2 (arrows in B,E).
(G-L) X-Gal stained Meox2+/− (G-I) and Meox2−/− (J-L) embryos
(E10.5) obtained after crossing with a transgenic 145-baMyf5nlacZ
line, withmagnifications of the dorsal aspect of the forelimbs shown in
H,I,K,L. There is a striking reduction in β-galactosidase positive cells
in themutant at this stage (red arrows). (M-O) X-Gal stained transient
transgenic embryos at E10.5, with a−58/−57baMyf5nlacZ transgene
(−58/−57) (M) or with the same transgene in which HBoxes 1-3
sequences in the145-bpsequencehavebeenmutated (−58/−57Mut
HBox1/2*/3) (N,O). An enlargement at the forelimb level is shown in
O.When all 3 HBox sequences are mutated transgene expression in
the forelimb (red arrow) is absent at E10.5. Expression in the
branchial arches and neural tube is due to sequences in the proximal
promoter region of Myf5 (baMyf5), present in the transgene.
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indication of co-binding of Meox2 and Pax3 or Six proteins to the
Hbox2 region. In Meox2 mutants, there is a reduction in Pax3
transcripts (Mankoo et al., 1999) and a lower level of Pax3 may also
impact the −145-bp enhancer, however from our transgenic
experiments we conclude that Meox2 directly affects Myf5
transcription. In the absence of Meox2, the delay in activation of
the transgene corresponds to a four somite interval at E10.5. The
low level of expression of the 145-Myf5nLacZ transgene in forelimb
buds of Meox2−/− E10.5 embryos is not due to a lack of myogenic
progenitor cells because these are clearly detected at a similar stage
using Pax3whole mount in situ hybridization (Fig. S2). Buchberger
et al. (2007), who did not detect a difference in Meox2 mutants,
probably missed the delay we observe at E10.5 by examining E11.5-
E13.5 embryos. We found that the delay of Myf5 activation in
Meox2 mutants, occurring via the 145-bp element, is compensated
in forelimbs by E12.5 and indeed no difference in Myosin Heavy
Chain expression was observed in Meox2 mutant limbs (B.S.M.,
unpublished). At E12.5, the delay is still observed in hindlimbs,
which suggests that the mechanism of early Myf5 activation by
Meox2 is similar in fore- and hindlimbs. Since mutation of Hbox1,
Hbox2 and Hbox3 sites prevents the correct onset of transgene
expression, while the HBox2* mutation alone leads to premature
activation of the transgene, we conclude that HBox1 and HBox3 are
the sites implicated in activation by Meox2, acting together with
Pax3 and Six1/4 on their respective binding sites. This suggests that
these factors, and especially Pax3, which is critical for activation,
compete favourably over Meox2 binding to HBox2 at the onset of
myogenesis, thus avoiding the steric hindrance seen when this site is
occupied by Msx1. Our results provide the first demonstration that
Meox2 directly activates a skeletal muscle determination gene, fine-
tuning the onset of myogenesis in the limb. Subsequently Meox2 is
not required in this context and other factors may intervene, such as
Mef1 or NFat which also have binding sites in the 145-bp sequence
(Buchberger et al., 2007).
Msx1, which is also expressed in myogenic progenitors that
migrate to the forelimb (Houzelstein et al., 1999), binds in vitro to
HBox2, but not to HBoxes 1 and 3. The HBox2 sequence is
identical to the consensus site for Msx1 binding to DNA
characterized in vitro (Catron et al., 1993; Hovde et al., 2001).
ChIP experiments confirm that Msx1 binds in vivo to the 145-bp
sequence, presumably at HBox2, at a stage when myogenic
progenitor cells delaminate from the hypaxial dermomyotome and
enter the forelimb bud from the somite, prior to Myf5 activation.
Msx1 is only expressed in the hypaxial dermomyotome at this axial
level, as confirmed by ChIP experiments on interlimb somites
which show no occupancy by Msx1. Transplantation of early
forelimb level somites from Msx1nlacZ/+ embryos into chick
embryos at the same axial level showed that β-galactosidase-
positive cells subsequently left the somites and entered the limb bud
(Houzelstein et al., 1999), leading us to conclude that we are
dealing with limb muscle progenitors. We saw no evidence for
formation of an inactivating complex between Pax3 and Msx1, in
the 145-bp Myf5 context, as reported previously for the MyoD
enhancer (Bendall et al., 1999). Instead we show that Msx1 binding
to HBox2 competes with binding of Pax3 or Six1/4, respectively to
sites 5′ and 3′of HBox2, due to steric hindrance since this is
alleviated by increasing the distance between these sites. Thus
Msx1 binding to HBox2 prevents binding of essential activators
and also probably exerts a direct repressive effect by recruiting
Polycomb as shown for MyoD (Wang et al., 2011) and/or by
recruitment of methyltransferase G9a and repressive H3K9me2 as
shown for this Myf5 regulatory region in C2 muscle cells
overexpressing Msx1 (Wang and Abate-Shen, 2012). In
transgenic analysis, when HBox2 is mutated, premature activation
of Myf5 in the hypaxial somite region and in myogenic progenitor
cells in the forelimb bud is observed, consistent with a role for
Msx1 in repressing Myf5 activation via this site. Expression of the
Msx1lacZ reporter allele in the Pax3-positive myogenic progenitors,
is rapidly lost when they reach the proximal region of the limb
where myogenic cells accumulate (Houzelstein et al., 1999). Thus
we propose down-regulation of Msx1 releases repression and
permits Pax3 and Six1/4 binding. This repression by Msx1 onMyf5
and also on MyoD (Bendall et al., 1999), will effectively prevent
the premature onset of myogenesis. When we examine the
phenotype of conditional Msx1flox/flox embryos where the floxed
alleles are inactivated by Cre recombinase in Pax3-expressing cells
(Pax3Cre/+), we do not detect a major difference in Myf5 activation
in these cells in the developing forelimb, but we see significantly
more Myf5-positive cells in the hypaxial dermomyotome as well as
immediately adjacent to this part of the somite at forelimb bud level,
at the onset of delamination and migration. Similar results were
obtained with Msx1flox/flox; Msx2flox/flox embryos, indicating that
Msx1 is primarily responsible and indeed Msx2 expression has not
been reported in somites (Bensoussan et al., 2008). This Msx1
mutant phenotype is transitory, most evident at the 28-30 somite
stage. By E11.5, we did not detect an increase in Myf5-positive
cells in the forelimb. In contrast, an increase inMyf5 transcripts had
been reported in the forelimbs ofMsx1mutant embryos at this stage
(Wang et al., 2011), however, since the in situ signal was generally
higher, it is not clear whether the control and mutant embryos were
strictly comparable. Since the effect that we observe is transitory
and limb muscle defects have not been reported in the absence of
Msx1 (Houzelstein et al., 1997; Satokata and Maas, 1994), it is
probable that other factors also intervene to repress prematureMyf5
activation. Up-regulation of the Myf5 transgene in myogenic
progenitors in the forelimb, as well as the hypaxial somite region,
when Hbox2 is mutated suggests that another homeodomain
binding factor may be involved. Lbx1 is a potential candidate,
however we did not observe binding of Lbx1 in EMSA experiments
(results not shown). Furthermore, although binding might have
exerted steric hindrance, Lbx1 appears to be an activator in the
myogenic context (Vasyutina et al., 2005). Other repressive
mechanisms may also operate, to prevent premature transcription
of Myf5. In addition to the 145-bp element within the −58/−57 kb
sequence used to test the functional effect of mutating HBox2, a
second conserved region contains a Smad binding site, which,
when mutated, led to ectopic Myf5 activation in the vicinity of the
somite (Buchberger et al., 2007). Bmp4 in lateral mesoderm
adjacent to the hypaxial somite has been shown to prevent
premature activation of MyoD in the chick embryo (Pourquié
et al., 1996) and it is therefore likely that BMP signalling acting
through the Smad site also re-inforces repression of Myf5
transcription during the migration of myogenic progenitor cells to
the limb. In these cells,MyoD transcription has also been shown to
be regulated by transcriptional repression exerted by the bHLH-
PAS transcription factor Sim2, acting on the MyoD core enhancer
(Havis et al., 2012). Repression of Myf5 was not observed when
Sim2 was overexpressed under conditions where MyoD was
downregulated in chick and Xenopus embryos (Havis et al.,
2012). This suggests that the two myogenic determination genes are
repressed by a combination of different mechanisms, to prevent
premature entry into the myogenic programme.
In conclusion, fine-tuning of the onset of Myf5 activation in
myogenic progenitor cells that migrate from the somite to the
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forelimb depends on the binding of homeodomain factors that
inhibit or activate transcription via the 145-bp regulatory sequence
at −57.5 kb. We propose that inhibition is normally exerted by
binding of Msx1 that interferes with the binding of Pax3 and Six1/4
and may also act as a transcriptional repressor. This prevents
premature activation of this myogenic determination gene in Pax3-
positive progenitor cells which would compromise the correct
localisation of skeletal muscles and also the maintenance of
myogenic progenitors required for subsequent muscle growth. In
addition to Pax3 and Six1/4 activation of the 145-bp limb element,
the initiation of Myf5 transcription also depends on Meox2 that
binds to additional homeodomain sites. A model recapitulating the
onset of Myf5 gene activation during forelimb development is
shown in Fig. 7. This example, for a myogenic determination gene,
illustrates the importance of transcriptional fine-tuning to ensure the
precise spatiotemporal expression of key regulatory factors during
development.
MATERIALS AND METHODS
Plasmid constructions used for transgenesis
All plasmid constructs used for transgenesis are derived from plasmid
pbaMyf5-nLacZ (Hadchouel et al., 2000), p−58/−57 and p−145-
baMyf5nLacZ (Bajard et al., 2006; Hadchouel et al., 2003) constructs.
Mutagenesis of homeodomain binding sites (HBox) was first performed
by PCR amplification with the Expand High Fidelity PCR System
(Roche), using as a template a plasmid in which the−58/−57 fragment had
been subcloned into the pGEMT-Easy vector (Promega) and two primers,
forward and reverse, complementary to their 5′ extremities as described in
Daubas et al. (2009). Mutations were successively carried out in HBox2, 3
and 1 using primers as described in Table S1. Then a HBox2* mutation
was introduced into the −58/−57 fragment, mutated in HBoxes 1, 2 and 3
using a primer HBox2* (see Table S1) and the QuickChange Multi Site-
Directed Mutagenesis kit (Stratagene). Mutations were checked by DNA
sequencing (GATCBiotech) and the mutated fragments were isolated from
pGEMT-Easy plasmids (Promega) and recloned into the pbaMyf5-nLacZ
vector.
Mouse lines, transgenesis and embryo analysis
TheMeox2+/− andMsx1nLacZ:+mouse lines have been described inMankoo
et al. (1999) and Houzelstein et al. (1997). TheMsx1Tag/Tag mouse line was
produced by inserting HA Tag in-frame in front of the Msx1 stop codon
followed by an IRES-nls mCherry cassette. After ES cell selection and
blastocyst injection, F1 mice born from germline chimaeras were bred with
FLPe transgenic mice to remove the neomycin cassette. Heterozygous
Msx1Tag/+ and homozygous Msx1Tag/Tag mice were viable and fertile,
indicating that the Msx1Tag allele is functional (Duval et al., 2014).
Immunodetection of the HA Tag in E10.5 Msx1Tag/+ embryos showed
correct expression. ConditionalMsx1 (a kind gift of Dr Robert Maxson, Los
Angeles, CA, USA) andMsx2 floxed alleles are respectively described in Fu
et al. (2007) and Bensoussan et al. (2008). The Pax3Cre/+ mouse line is
described in Engleka et al. (2005). Transgenic mice were obtained on a
C57BL/6JxSJL genetic background. Experiments were performed in
accordance with the European Community guidelines (2010/63/UE) and
with French national regulations for the care and use of laboratory animals.
All transgenesis experiments were carried out by injecting vectorless
plasmid inserts and performed by the Centre d’Ingénierie Génétique Murine
of the Pasteur Institute. The −58/−57baMyf5nLacZ transgenic mouse line
was as described previously (Hadchouel et al., 2003). Hetezygous
transgenic males were crossed with non-transgenic females (C57BL/
6JxSJL F1). Embryos were staged taking E0.5 as the day of the vaginal plug
and somites were counted for more precise staging. Most functional studies
were carried out by transient transgenesis. Embryos were screened for
transgene expression by X-Gal staining as described in Tajbakhsh et al.
(1996). The number of transgenic embryos analysed in each experiment is
indicated in Table S2.
Electrophoretic mobility shift assays
A 1044 bp SphI-XhoI fragment corresponding to mouseMeox-2 cDNAwas
blunted and cloned into theEcoRV site of the pcDNA3 plasmid (Invitrogen).
The Pax3 expression plasmid was a gift from F. Relaix (Paris Est-Créteil
University, Créteil) and consisted of a full length mouse Pax3 cDNA cloned
into a pcDNA3.1 vector (Invitrogen). Six1 and Six4 expression vectors were
gifts from P.Maire (Institut Cochin, Paris). Full length Six1 and Six4 cDNAs
were cloned into the pCR3 CMV T7 expression vector (Invitrogen), as
described in Spitz et al. (1998). Plasmid constructions for recombinant
Fig. 7. Model for activation of Myf5 transcription via the 145-bp core element, during early forelimb bud development. Binding of Msx1 interferes with
binding of Pax3 and Six1/4 to the enhancer, and this prevents premature activation of Myf5 expression in myogenic progenitors in the hypaxial somite. Binding of
Pax3 and Six1/4 in conjunction with Meox2 binding to flanking homeobox sites in the enhancer is required for normal activation of Myf5 expression. Maintenance
of Myf5 expression in the myoblasts once they have migrated into the limb is dependent on Pax3 and Six1/4 but is independent of Meox2 activity. Abbreviations:
DM, dermomyotome; M, myotome; HDM, hypaxial dermomyotome; PMM, pre-muscle masses.
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Msx1-C-HA and Msx2-C-Flag proteins were designed by N.D. Fragments
corresponding to full length coding regions of Msx1-C-HA and Msx2-C-
Flag were subcloned into pcDNA3.1+ (Invitrogen) and pCMV-TnT
(Promega) vectors, respectively. Expression plasmid DNAs were used to
synthesize proteins in vitro with the TnT T7 Quick Coupled Transcription/
Translation System (Promega). Electrophoretic mobility shift assays
(EMSA) were performed as described in Bajard et al. (2006). P32-γATP
labelled oligos, containing HBox1, 2 or 3 are listed in Table S1, as well as the
elongated core enhancer probe, LongPaxHBox2Six (containing spacers
between the HBox2 site and Pax3/Six binding sites). Except when specified
otherwise, proteins to be tested together were added simultaneously. One
microliter of either anti-HA (Roche Applied Science), anti-FLAG M2
(Sigma), rabbit polyclonal anti-Meox2 (B. Mankoo), mouse monoclonal
anti-Pax3-C (DSHB) or rabbit anti-Six4 (Sigma) were added to EMSA
binding reactions for supershift assays.
Immunocytochemistry
Immunodetection was performed on X-Gal stained 20 µm cryostat sections,
using monoclonal mouse anti-Pax3-C antibodies (DSHB) and the Vector
M.O.M (Mouse on Mouse) Peroxidase kit (Vector Laboratories). Sections
of control andMsxmutants shown in Fig. 5Awere 10 µm thick. Monoclonal
mouse anti-Pax3-C antibodies (1:250, DSHB), rabbit polyclonal anti-Myf5-
C20 (1:250, Santa Cruz), Alexa Fluor 488 Anti-Mouse IgGs and Alexa
Fluor 546 Anti-Rabbit IgGs (1:500, Molecular Probes) were employed for
immunofluorescence experiments. Nuclear staining was with Hoechst
solution.
In situ hybridisation
Whole-mount in situ hybridization on mouse embryos was performed as
described in Daubas et al. (2000) using digoxigenin-labelled antisenseMyf5
(Ott et al., 1991) or Pax3 (kindly provided by Dr P. Gruss, Max Planck
Institute, Gottingen) riboprobes. Automated in situ hybridization on cryostat
embryo sections was performed with an InsituPro VSi apparatus (Intavis
Bioanalytical Instruments) using a digoxigenin-labelled antisense Msx1
riboprobe (Lyons et al., 1992).
ChIP-qPCR
The trunk at forelimb level, including forelimbs, or interlimb regions were
dissected from E10-10.5 mouse embryos and the protocol used for
chromatin immunoprecipitation (ChIP) and qPCR analysis was as
described in Daubas and Buckingham (2013). The following antibodies
were used: rat monoclonal anti-HA (high affinity, clone 3F10, Roche –
aHA1), rabbit polyclonal anti-HA (ChIP grade, Abcam – aHA2), rabbit
polyclonal anti-Meox2 (B.S.M.), rabbit polyclonal anti-histone H3 (tri-
methyl K4) (ChIP grade, Abcam) and IgG from rabbit serum (Sigma). qPCR
primer sequences are listed in Table S1. All analyses were carried out in 96-
well plates using a StepOnePlus PCR machine (Applied Biosystems) and
the FastStart Universal SYBR GreenMaster (Rox) (Roche). qPCR reactions
were performed in triplicate with each of 3 different preparations of
chromatin prepared either from forelimb or interlimb regions of pooled
embryos. 5 µl of DNA solution were used per reaction, corresponding to 1 or
0.1 µl of immunoprecipitated DNA or Input DNA, respectively. Standard
curves of all primers were performed to check for efficient amplification
(above 90%). Melting curves were also performed to verify production of
single DNA species with each primer pair. Relative levels of expression in
each assay were obtained through the ΔΔCt method (Livak and Schmittgen,
2001). Fold changes in occupancy, compared to negative control regions,
are equal to 2−ΔΔCt.
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